Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06161415
Other study ID # 71341
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date April 2024
Est. completion date October 2024

Study information

Verified date April 2024
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The LION Study is a prospective, single-center phase 1 clinical trial to evaluate the safety, tolerability, and distribution of Laquinimod administered as topical eye drops for two weeks in human participants.


Description:

Participants who fulfill the study eligibility criteria and who are planned to undergo a pars plana vitrectomy will be enrolled in the study. Eligible participants scheduled for a diagnostic vitrectomy may also be enrolled. The study will consist of two stages: Stage One - Open label dose escalation: Up to three subsequent dose-escalation groups will receive Laquinimod eye drops for 2 weeks and samples will be assayed for Laquinimod concentration in aqueous humor, vitreous and plasma. Stage Two- Randomized, Controlled Comparison of 2 Laquinimod doses: After the dose escalation cohorts are analysed, 2 Laquinimod doses will be selected for a randomized comparison. The doses in stage 2 will not exceed those studied in stage 1.


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date October 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age 18 years or older 2. Participants who are capable and willing to provide informed consent and follow study instructions. 3. Participants who are scheduled to undergo pars plana vitrectomy (PPV). 4. Participants with intraocular pressure (IOP) = 5 mmHg and =22 mmHg in study eye 5. Women who are not pregnant or lactating, are post-menopausal or have undergone a sterilization procedure. Exclusion Criteria: 1. Participants with active periocular or ocular infectious disease (e.g., blepharitis, scleritis, or conjunctivitis, keratitis or endophthalmitis). 2. Participants with active infectious uveitis 3. Participants with a history of prior intraocular or extraocular surgery within 90 days of study enrollment 4. Participant with a history of intravitreal steroids administered to the study eye within 90 days of enrollment. 5. Participants with a history of intravitreal injection of VEGF inhibitors within 30 days of enrollment 6. Use of any topical cyclosporine or corticosteroid or other specified (i.e. calcineurin inhibitors) ophthalmic medication in the study eye for any reason within 14 days of enrollment and before the surgery 7. Use of medication consisting of a strong or moderate inhibitor of CYP3A4 within 2 weeks of Baseline visit (and during the study). 8. Use of medication consisting of a strong inducer of CYP3A4 within 2 weeks of Baseline visit (and during the study) 9. Mild, moderate, or severe hepatic impairment (any of Child-Pugh Score A, B, and C) 10. Moderate or severe renal impairment (GFR =60 mL/min) 11. History of HIV disease or other immunodeficiency disorder 12. History of acute hepatitis A (IgM positive), hepatitis B, or hepatitis C 13. History of organ or bone marrow transplant 14. Presence of malignancy under active treatment 15. Any other acute or chronic medical condition that would, in the judgment of the study investigators, reasonably preclude participation in the clinical study 16. Already enrolled in a clinical trial. 17. Any condition that would prevent the investigator from acquiring images of the eye as required per protocol

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Laquinimod eye drops
n Laquinimod eye drops 10 mg/ml Dose: Dosing frequency will depend on the groups assigned

Locations

Country Name City State
United States Spencer Center for Vision Research at the Byers Eye Institute Palo Alto California

Sponsors (2)

Lead Sponsor Collaborator
Quan Dong Nguyen Global Ophthalmic Research Center (GORC)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Concentration of Laquinimod in aqueous humor and vitreous samples of human participants Assessment of concentration of Laquinimod in aqueous humor and vitreous samples of human by biolanalysis in specialized lab participants on Day 14 of Laquinimod eye-drop administration. After 2 weeks of study drug administration
Primary Concentration of Laquinimod in plasma of human participants Assessment of concentration of Laquinimod in plasma of human participants on Day 14 of Laquinimod in specialized lab eye-drop administration. participants on Day 14 of Laquinimod eye-drop administration. After 2 weeks of study drug administration
Secondary Safety Assessment Any Adverse events: ocular and non-ocular at Post operative Day 1 and Post operative Day 8 compared to baseline. Baseline to end of Study at 22-30days
See also
  Status Clinical Trial Phase
Completed NCT03995979 - Inflammation and Protein Restriction N/A
Completed NCT03255187 - Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT03577223 - Egg Effects on the Immunomodulatory Properties of HDL N/A
Completed NCT04383561 - Relationship Between LRG and Periodontal Disease N/A
Active, not recruiting NCT03622632 - Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
Completed NCT06216015 - Exercise Training and Kidney Transplantation N/A
Completed NCT04856748 - Nomogram to Diagnose Prostatic Inflammation (PIN) in Men With Lower Urinary Tract Symptoms
Completed NCT05529693 - Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population N/A
Recruiting NCT05670301 - Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases N/A
Recruiting NCT05415397 - Treating Immuno-metabolic Depression With Anti-inflammatory Drugs Phase 3
Recruiting NCT04543877 - WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study Early Phase 1
Recruiting NCT05775731 - Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Completed NCT03429920 - Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors N/A
Completed NCT06065241 - Quantifiably Determine if the Botanical Formulation, LLP-01, Has a Significant Clinical Effect on Proteomic Inflammatory Biomarkers and Epigenetic Changes in Healthy, Older Individuals. N/A
Completed NCT05864352 - The Role of Dietary Titanium Dioxide on the Human Gut Microbiome and Health
Completed NCT03318731 - Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males N/A
Not yet recruiting NCT06134076 - Comparing Effects of Fermented and Unfermented Pulses and Gut Microbiota N/A
Not yet recruiting NCT05910489 - Micro and Nanoplastics in Greenhouse Workers: Biomarkers of Exposure and Effect